Viridian Therapeutics, Inc. VRDN Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Operating margin | -543.9%-30.9pp | -512.9%-49.4pp | -463.5%+121,368pp | -121,831.1%-10,240pp | -111,591.1%-12,573pp | |
| Net margin | -508.5%-24.9pp | -483.6%-57.0pp | -426.6%+112,380pp | -112,806.9%-10,715pp | -102,092.4%-12,705pp | |
| Returns | ||||||
| Return on equity | -58.1%-9.0pp | -49.2%+0.7pp | -49.9%+16.0pp | -65.9%-13.9pp | -51.9%-3.5pp | |
| Return on invested capital | -76.5%-11.7pp | -64.8%+9.1pp | -73.9%+12.0pp | -85.9%-20.1pp | -65.8%-1.9pp | |
| Efficiency | ||||||
| Asset turnover | 0.1×0.0× | 0.1×0.0× | 0.1×+0.1× | 0×0.0× | 0×0.0× | |
| Liquidity | ||||||
| Current ratio | 15.1×+2.5× | 12.6×+1.4× | 11.3×+0.3× | 11×-8.5× | 19.5×+4.1× | |
| Leverage | ||||||
| Debt-to-equity | 0.1×0.0× | 0.1×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Valuation | ||||||
| Market capitalization | $2B-32.7% | $2.97B+68.5% | $1.76B+47.3% | $1.2B+8.9% | $1.1B-27.7% | |
| Price / sales | 28.2×-13.7× | 41.9×+17.0× | 24.9×-3,897× | 3,921.8×+285× | 3,637.1×-1,391× | |
| Price / book | 3.1×-1.0× | 4.1×+0.6× | 3.5×+1.2× | 2.3×+0.5× | 1.8×-0.4× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Viridian Therapeutics, Inc.'s profit margins?
- Viridian Therapeutics, Inc. (VRDN) runs a 36.3% gross margin and a -543.9% operating margin, with a -508.5% net margin.
- Where do Viridian Therapeutics, Inc.'s ratios come from?
- Every ratio is computed from Viridian Therapeutics, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
